Pharmacotherapy options for advanced thyroid cancer: A systematic review

Drugs

Volumn 72, Issue 1, 2012, Pages 67-85

  Lerch, Christian ^a   Richter, Bernd ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Axitinib; Celecoxib; Fosbretabulin; Gefitinib; Imatinib; Lenalidomide; Motesanib; Pazopanib; Plitidepsin; Rosiglitazone; Sorafenib; Sunitinib; Thalidomide; Thyroid cancer; Vandetanib; Vorinostat

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; CABOZANTINIB; CELECOXIB; COMBRETASTATIN A4 PHOSPHATE; DEHYDRODIDEMNIN B; DOXORUBICIN; GEFITINIB; IMATINIB; MOTESANIB; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN P53; RADIOACTIVE IODINE; RAS PROTEIN; ROSIGLITAZONE; SORAFENIB; SUNITINIB; THALIDOMIDE; TIPIFARNIB; TRANSCRIPTION FACTOR PAX8; VANDETANIB; VORINOSTAT;

ABDOMINAL PAIN; ACTINOMYCOSIS; ACUTE CHOLECYSTITIS; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPLASTIC THYROID CANCER; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CELL COUNT; BLURRED VISION; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHOLELITHIASIS; COLON PERFORATION; CONGESTIVE HEART FAILURE; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEHYDRATION; DEPRESSION; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOXICITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ERYTHEMA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; FOOT PAIN; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENE REARRANGEMENT; HAND FOOT SYNDROME; HAND PAIN; HEADACHE; HEART LEFT VENTRICLE FAILURE; HORMONE INHIBITION; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOTHYROIDISM; HYPOXIA; ILEUS; INFECTION; KERATOACANTHOMA; LARYNGITIS; LARYNX EDEMA; LEUKOPENIA; LIVER FUNCTION TEST; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALAISE; MEDULLARY THYROID CANCER; MELENA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYALGIA; MYOPATHY; NAUSEA; NEUTROPENIA; ODYNOPHAGY; OSTEOMYELITIS; OVERALL SURVIVAL; PAIN; PALMAR PLANTAR ERYTHEMA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SLEEP DISORDER; SOMNOLENCE; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; SYNCOPE; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TONGUE PAIN; TOOTH PAIN; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR PAIN; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYROID FUNCTION TESTS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84055184780     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11594890-000000000-00000     Document Type: Review

References (45)

1. Sherman SI. Thyroid carcinoma. Lancet 2003 Feb 8; 361 (9356): 501-11 (Pubitemid 36173719)
2. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11): 1167-214
3. Sciuto R, Romano L, Rea S, et al. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol 2009 Oct; 20 (10): 1728-35
4. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006 Aug; 91 (8): 2892-9 (Pubitemid 44271732)
5. Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010 Aug; 39 (6): 775-83
6. Rendl G, Manzl M, Hitzl W, et al. Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2008 Sep; 69 (3): 497-505
7. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006 Nov 1; 107 (9): 2134-42 (Pubitemid 44665646)
8. Neff RL, Farrar WB, Kloos RT, et al. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008 Jun; 37 (2): 525-38, xi (Pubitemid 351711678)
9. Brignardello E, Gallo M, Baldi I, et al. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 2007 Apr; 156 (4): 425-30 (Pubitemid 46672642)
10. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma: treatment outcome and prognostic factors. Cancer 2005 Apr 1; 103 (7): 1330-5 (Pubitemid 40410726)
11. Yau T, Lo CY, Epstein RJ, et al. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol 2008 Sep; 15 (9): 2500-5
12. Fassnacht M, Kreissl MC, Weismann D, et al. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 2009; 123 (1): 117-41
13. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol 2010 Sep 1; 80 (5): 592-601
14. Al-Humadi H, Zarros A, Al-Saigh R, et al. Genetic basis and gene therapy trials for thyroid cancer. Cancer Genomics Proteomics 2010 Jan-Feb; 7 (1): 31-49
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 Feb 2; 92 (3): 205-16 (Pubitemid 30099779)
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 2009 Jan; 45 (2): 228-47
17. Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26 (29): 4708-13
18. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008; 18 (3): 317-23 (Pubitemid 351415790)
19. Frank-Raue K, Fabel M, Delorme S, et al. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007; 157 (2): 215-20 (Pubitemid 47233127)
20. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007 Sep; 92 (9): 3466-9 (Pubitemid 47435321)
21. Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010; 20 (9): 975-80
22. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008 Jul 3; 359 (1): 31-42 (Pubitemid 351931094)
23. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; 27 (23): 3794-801
24. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010; 11 (10): 962-72
25. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008 Oct 10; 26 (29): 4714-9
26. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009 Apr 1; 27 (10): 1675-84
27. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161 (6): 923-31
28. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28 (14): 2323-30
29. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16 (21): 5260-8
30. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28 (5): 767-72
31. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95 (6): 2664-71
32. Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91 (6): 2201-4 (Pubitemid 43855005)
33. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009 Mar; 19 (3): 233-40
34. Baudin E, Droz JP, Paz-Ares L, et al. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. Am J Clin Oncol 2010; 33 (1): 83-8
35. Kebebew E, Lindsay S, Clark OH, et al. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 2009; 19 (9): 953-6
36. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007; 17 (7): 663-70 (Pubitemid 47311556)
37. Woyach JA, Kloos RT, Ringel MD, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009; 94 (1): 164-70
38. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. Epub 2011 May 23
39. Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011; 165 (2): 315-22
40. Hong DS, Cabanillas ME, Wheler J, et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 2011; 96 (4): 997-1005
41. Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359 (1): 31-42 (Pubitemid 351931094)
42. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27 (10): 1675-84
43. Glasziou P, Chalmers I, Rawlins M, et al. When are randomised trials unnecessary? Picking signal from noise. BMJ 2007 Feb 17; 334 (7589): 349-51
44. de la Fouchardiere C, Droz JP. Targeted therapies and thyroid cancer: an update. Anticancer Drugs 2011 Aug; 22 (7): 688-99
45. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). ASCO Meeting Abstracts 2010 Jun 14; 28 (15 Suppl. ): 5503